These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 23336039)

  • 1. Revisiting serotonin reuptake inhibitors and the therapeutic potential of "uptake-2" in psychiatric disorders.
    Daws LC; Koek W; Mitchell NC
    ACS Chem Neurosci; 2013 Jan; 4(1):16-21. PubMed ID: 23336039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Organic Cation Transporters in Psychiatric Disorders.
    Daws LC
    Handb Exp Pharmacol; 2021; 266():215-239. PubMed ID: 34282486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unfaithful neurotransmitter transporters: focus on serotonin uptake and implications for antidepressant efficacy.
    Daws LC
    Pharmacol Ther; 2009 Jan; 121(1):89-99. PubMed ID: 19022290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of agomelatine and selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors in major depressive disorder: A meta-analysis of head-to-head randomized clinical trials.
    Huang KL; Lu WC; Wang YY; Hu GC; Lu CH; Lee WY; Hsu CC
    Aust N Z J Psychiatry; 2014 Jul; 48(7):663-71. PubMed ID: 24604920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Other Antidepressants.
    Schwasinger-Schmidt TE; Macaluso M
    Handb Exp Pharmacol; 2019; 250():325-355. PubMed ID: 30194544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The dual-action hypothesis: does pharmacology matter?
    Shelton RC
    J Clin Psychiatry; 2004; 65 Suppl 17():5-10. PubMed ID: 15600376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The serotonin transporter in psychiatric disorders: insights from PET imaging.
    Spies M; Knudsen GM; Lanzenberger R; Kasper S
    Lancet Psychiatry; 2015 Aug; 2(8):743-755. PubMed ID: 26249305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serotonin Transporter Gene Polymorphisms and Selective Serotonin Reuptake Inhibitor Tolerability: Review of Pharmacogenetic Evidence.
    Zhu J; Klein-Fedyshin M; Stevenson JM
    Pharmacotherapy; 2017 Sep; 37(9):1089-1104. PubMed ID: 28654193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Association Between Antidepressant Effect of SSRIs and Astrocytes: Conceptual Overview and Meta-analysis of the Literature.
    Chen B; Zhang M; Ji M; Gong W; Chen B; Zorec R; Stenovec M; Verkhratsky A; Li B
    Neurochem Res; 2021 Oct; 46(10):2731-2745. PubMed ID: 33527219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoamine transporter gene polymorphisms and antidepressant response in koreans with late-life depression.
    Kim H; Lim SW; Kim S; Kim JW; Chang YH; Carroll BJ; Kim DK
    JAMA; 2006 Oct; 296(13):1609-18. PubMed ID: 17018806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serotonergic drugs for depression and beyond.
    Stahl SM; Lee-Zimmerman C; Cartwright S; Morrissette DA
    Curr Drug Targets; 2013 May; 14(5):578-85. PubMed ID: 23531115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy of atypical antipsychotics in depressive syndromes].
    Quintin P; Thomas P
    Encephale; 2004; 30(6):583-9. PubMed ID: 15738862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decynium-22 enhances SSRI-induced antidepressant-like effects in mice: uncovering novel targets to treat depression.
    Horton RE; Apple DM; Owens WA; Baganz NL; Cano S; Mitchell NC; Vitela M; Gould GG; Koek W; Daws LC
    J Neurosci; 2013 Jun; 33(25):10534-43. PubMed ID: 23785165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Milnacipran and selective serotonin reuptake inhibitors in major depression.
    Lopez-Ibor J; Guelfi JD; Pletan Y; Tournoux A; Prost JF
    Int Clin Psychopharmacol; 1996 Sep; 11 Suppl 4():41-6. PubMed ID: 8923126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vortioxetine: a New Treatment for Major Depressive Disorder.
    Connolly KR; Thase ME
    Expert Opin Pharmacother; 2016; 17(3):421-31. PubMed ID: 26679430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does pretreatment testing for serotonin transporter polymorphisms lead to earlier effects of drug treatment in patients with major depression? A decision-analytic model.
    Smits KM; Smits LJ; Schouten JS; Peeters FP; Prins MH
    Clin Ther; 2007 Apr; 29(4):691-702. PubMed ID: 17617292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective Serotonin Reuptake Inhibitors and Serotonin and Noradrenaline Reuptake Inhibitors Improve Cognitive Function in Partial Responders Depressed Patients: Results from a Prospective Observational Cohort Study.
    Castellano S; Ventimiglia A; Salomone S; Ventimiglia A; De Vivo S; Signorelli MS; Bellelli E; Santagati M; Cantarella RA; Fazio E; Aguglia E; Drago F; Di Nuovo S; Caraci F
    CNS Neurol Disord Drug Targets; 2016; 15(10):1290-1298. PubMed ID: 27712575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Future directions for serotonin and antidepressants.
    Artigas F
    ACS Chem Neurosci; 2013 Jan; 4(1):5-8. PubMed ID: 23336036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drugs which influence serotonin transporter and serotonergic receptors: Pharmacological and clinical properties in the treatment of depression.
    Taciak PP; Lysenko N; Mazurek AP
    Pharmacol Rep; 2018 Feb; 70(1):37-46. PubMed ID: 29309998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The medical management of depression.
    Mann JJ
    N Engl J Med; 2005 Oct; 353(17):1819-34. PubMed ID: 16251538
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.